Anorexia Nervosa

5
Pipeline Programs
7
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
1
SOMATROPINE* : Norditropine® simplexx®Phase 2/31 trial
Active Trials
NCT01626833Completed15Est. Mar 2021
Compass Therapeutics
2 programs
2
PsilocybinPhase 21 trial
PsilocybinPhase 21 trial
Active Trials
NCT05481736Completed32Est. Nov 2024
NCT04661514CompletedEst. Jun 2022
Compass Pathways
Compass PathwaysUK - Cheshire
2 programs
2
PsilocybinPhase 2
PsilocybinPhase 2
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
Drug Transport in Patients With Anorexia NervosaN/A1 trial
GlucoseN/A3 trials
Active Trials
NCT00176150Unknown
NCT04307875Unknown3,000Est. Sep 2022
NCT03075371Completed85Est. Feb 2019
+1 more trials
Alliance Pharmaceuticals
2 programs
Exposure Therapy + D-CycloserineN/A1 trial
Exposure Therapy for ANN/A1 trial
Active Trials
NCT00755820Completed32Est. Jan 2012
NCT01174602Completed40Est. Oct 2014
BrainsWay
BrainsWayJerusalem, Israel
1 program
Deep Insula-coil rTMSN/A1 trial
Active Trials
NCT03144986CompletedEst. Aug 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo NordiskSOMATROPINE* : Norditropine® simplexx®
Compass TherapeuticsPsilocybin
Compass TherapeuticsPsilocybin
Heidelberg PharmaGlucose
Heidelberg PharmaGlucose
BrainsWayDeep Insula-coil rTMS
Heidelberg PharmaGlucose
Alliance PharmaceuticalsExposure Therapy for AN
Alliance PharmaceuticalsExposure Therapy + D-Cycloserine

Clinical Trials (10)

Total enrollment: 3,304 patients across 10 trials

NCT01626833Novo NordiskSOMATROPINE* : Norditropine® simplexx®

Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone

Start: Mar 2013Est. completion: Mar 202115 patients
Phase 2/3Completed
NCT05481736Compass TherapeuticsPsilocybin

Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study

Start: Oct 2022Est. completion: Nov 202432 patients
Phase 2Completed
NCT04661514Compass TherapeuticsPsilocybin

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

Start: May 2021Est. completion: Jun 2022
Phase 2Completed
NCT00176150Heidelberg PharmaDrug Transport in Patients With Anorexia Nervosa

Drug Transport in Patients With Anorexia Nervosa

N/AUnknown
NCT04307875Heidelberg PharmaGlucose

Hypertension and Diabetes Assessment in the Rohingya Refugee Population and in the Host Communities in Bangladesh

Start: Oct 2021Est. completion: Sep 20223,000 patients
N/AUnknown
NCT03075371Heidelberg PharmaGlucose

Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa

Start: Sep 2014Est. completion: Feb 201985 patients
N/ACompleted
NCT03144986BrainsWayDeep Insula-coil rTMS

Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa

Start: Sep 2012Est. completion: Aug 2017
N/ACompleted
NCT01580176Heidelberg PharmaGlucose

Continuous GlucoseMonitor for Measurement of Blood Glucose Level

Start: Mar 2012Est. completion: Mar 2013100 patients
N/ACompleted
NCT01174602Alliance PharmaceuticalsExposure Therapy for AN

Inpatient Exposure Therapy and Response Prevention & Cognitive Remediation Therapy for Anorexia Nervosa

Start: Nov 2009Est. completion: Oct 201440 patients
N/ACompleted
NCT00755820Alliance PharmaceuticalsExposure Therapy + D-Cycloserine

Food Exposure Therapy in Anorexia Nervosa

Start: Jan 2008Est. completion: Jan 201232 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space